Efficacy, Safety And Dosage Of Afatinib In Patients With Non-Small Cell Lung Cancer After Failure Of Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-Tki)

被引：0
|
作者：
Park, C. [1 ]
Kim, T. [1 ]
Shin, H. [2 ]
Ban, H. [2 ]
Lim, J. [1 ]
Kwon, Y. [2 ]
Oh, I. [1 ]
Kim, Y. [1 ,2 ]
Lim, S. [2 ]
Kim, Y. [1 ,2 ]
机构：
[1] Chonnam Natl Univ, Hwasun Hosp, Hawsun, Jeonnam, South Korea
[2] Chonnam Natl Univ Hosp, Gwangju, South Korea
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
lung cancer; EGFR; afatinib;
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6676
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
    Chen, Dougfang
    Chu, Tianqing
    Chang, Qing
    Zhang, Yanwei
    Xiong, Liwen
    Qiao, Rong
    Teng, Jiajun
    Han, Baohui
    Zhong, Runbo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (09)
  • [42] Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
    Asami, Kazuhiro
    Atagi, Shinji
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 646 - 659
  • [43] CYTOKERATIN 19 FRAGMENT (CYFRA21-1) PREDICTS THE EFFICACY OF THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) IN NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATION
    Tanaka, K.
    Hata, A.
    Kaji, R.
    Fujita, S.
    Takeshita, J.
    Matsumoto, T.
    Monden, K.
    Nagata, K.
    Nanjo, S.
    Otsuka, K.
    Tachikawa, R.
    Otsuka, K.
    Hayashi, M.
    Tomii, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 137 - 138
  • [44] Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer
    Yang, Guangdie
    Yao, Yinan
    Zhou, Jianya
    Zhao, Qiong
    ONCOLOGY REPORTS, 2012, 27 (06) : 2066 - 2072
  • [45] Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI)
    Aitken, K.
    Popat, S.
    Nutting, C.
    McDonald, F.
    LUNG CANCER, 2015, 87 : S30 - S30
  • [46] STUDY OF THE SAFETY AND EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN 97 PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Ishibashi, M.
    Ogawa, K.
    Motizuki, S.
    Hanada, S.
    Uruga, H.
    Takaya, H.
    Miyamoto, A.
    Morokawa, N.
    Fujii, T.
    Kishi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 433 - 433
  • [47] The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations
    Lin, Jing-Hui
    Lin, Dong
    Xu, Ling
    Wang, Qiang
    Hu, Hui-Hua
    Xu, Hai-Peng
    He, Zhi-Yong
    ONCOTARGET, 2017, 8 (02) : 3412 - 3421
  • [48] THE ROLE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Mok, Tony
    ANNALS OF ONCOLOGY, 2010, 21 : 5 - 5
  • [49] Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer
    Martin-Fernandez, Marisa L.
    CANCERS, 2022, 14 (03)
  • [50] Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
    Zaarour, Mazen
    Weerasinghe, Chanudi
    Nazha, Bassel
    Hassan, Samer
    Atallah, Jean-Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1327 - 1336
12345